Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04026685
Other study ID # 2019-00866; qu18Buddeberg
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 9, 2020
Est. completion date February 5, 2021

Study information

Verified date February 2021
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spinal anaesthesia is the anaesthetic technique of choice for elective caesarean delivery. Hypotension, a result of the decrease in systemic vascular resistance caused by spinal anaesthesia, is a frequent complication occurring in up to 80%. This study is to investigate fluid loading plus vasopressors to vasopressors alone to maintain stable maternal haemodynamics in elective caesarean delivery. The effect of the two methods (continuous prophylactic phenylephrine infusion with and without crystalloid co-loading) on maternal haemodynamics will be compared using the Starling SV Monitor. The Starling SV device is a non invasive cardiac output monitor (NICOM) which is certified and validated for the use in pregnancy.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date February 5, 2021
Est. primary completion date February 5, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ability to give informed consent - Term uncomplicated singleton pregnancy - Undergoing elective caesarean section under spinal anaesthesia - Weight: 50-100kg - Height: 150-180cm - Healthy term fetus Exclusion Criteria: - Inability to give informed consent - Multiple pregnancy - Clinically significant concomitant disease states (e.g. hypertension, cardiac disease, severe asthma requiring regular medication, comorbidities affecting the autonomous nervous system, renal disease) - On any cardiovascular medication - Complications of pregnancy (e.g. preeclampsia, intrauterine growth restriction, fetal malformations) - Known or suspected non-compliance, drug or alcohol abuse - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the participant, - Participation in another study with investigational drug within the 30 days preceding and during the present study, - Previous enrolment into the current study, - Enrolment of the investigator, his/her family members, employees and other dependent persons - Any fetal pathology (e.g. fetal malformations, rupture of membranes before caesarean section, oligohydramnios, polyhydramnios, suspected chorioamnionitis)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Phenylephrine infusion
continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
Phenylephrine infusion and Ringer-Acetate bolus
continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL

Locations

Country Name City State
Switzerland Department of Anaesthesiology, University Hospital of Basel (USB) Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in maternal cardiac output (CO) CO measured by area under the curve (AUC) (L/min.) measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping
Secondary Change in maternal heart rate Change in maternal heart rate measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping
Secondary Change in maternal diastolic and systolic blood pressure Change in maternal diastolic and systolic blood pressure (mmHg) measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping
Secondary incidence of maternal nausea incidence of maternal Nausea (number) measured every minute after induction of spinal anaesthesia (=baseline) until 5 minutes after cord clamping
Secondary Change in Apgar scores The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are summarized using words chosen to form a backronym (Appearance, Pulse, Grimace, Activity, Respiration). at 1 and 5 minutes after delivery
Secondary Change in umbilical cord pH Change in umbilical cord pH at 1 and 5 minutes after delivery